Table 1.
Demographics and clinical scores
| Controls | PD | MSA-P | PSP | P | |
|---|---|---|---|---|---|
| No. of subjects | 37 | 35 | 16 | 17 | - |
| Sex, female/malea | 14/23 | 11/24 | 10/6 | 4/13 | 0.100 |
| Ageb | 70.4 ± 7.8 | 71.0 ± 7.4 | 66.4 ± 8.2 | 72.5 ± 9.7 | 0.152 |
| Disease durationb | - | 3.4 ± 3.6 | 4.1 ± 3.3 | 3.3 ± 2.9 | 0.745 |
| LEDD (mg/dy)c | - | 706.5 ± 426.0 | 752.3 ± 279.4 | 558.8 ± 282.1 | 0.264 |
| H & Yc | 0.4 ± 1.0 | 2.5 ± 1.2 | 3.4 ± 1.1 | 3.2 ± 1.0 | <0.001 |
| MoCAc | 25.0 ± 2.4 | 22.5 ± 4.2 | 23.9 ± 2.6 | 19.8 ± 4.7 | <0.001 |
| HAM-Ac | 4.5 ± 4.6 | 9.0 ± 6.5 | 11.1 ± 8.9 | 8.4 ± 5.7 | 0.001 |
| HAM-Dc | 2.6 ± 3.1 | 6.7 ± 5.0 | 8.1 ± 7.5 | 5.2 ± 5.0 | <0.001 |
| UPDRS-Ic | 4.1 ± 4.5 | 11.8 ± 8.2 | 11.9 ± 8.4 | 10.8 ± 6.7 | <0.001 |
| UPDRS-IIc | 1.4 ± 4.3 | 14.9 ± 13.3 | 22.6 ± 13.5 | 26.0 ± 12.7 | <0.001 |
| UPDRS-IIIc | 7.9 ± 13.2 | 37.3 ± 27.3 | 50.5 ± 19.1 | 41.8 ± 26.5 | <0.001 |
Data represent sums or mean ± standard deviation.
a
Group differences using the Chi-square test.
b
Group differences using one-way analysis of variance.
c
Group differences using one-way analysis of covariance with adjustments for age and sex.
Abbreviations: PD = Parkinson’s disease; MSA-P = multiple system atrophy (parkinsonian type); PSP = progressive supranuclear palsy; LEDD = levodopa equivalent daily dose; H & Y = Hoehn and Yahr Stage; MoCA = Montreal Cognitive Assessment; HAM-A = Hamilton Anxiety Rating Scale; HAM-D = Hamilton Depression Rating Scale; UPDRS-I, -II, -III = Unified Parkinson’s Disease Rating Scale Parts I, II, and III